ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
ISIS 104838 is an antisense oligonucleotide drug that reduces the production of a specific
protein called tumor necrosis factor (TNF-alpha), a substance that contributes to joint pain
and swelling in rheumatoid arthritis. ISIS 104838 works by blocking TNF-alpha messenger RNA,
the "instruction" molecule that is required for the production of TNF-alpha protein. This
trial will assess the safety and efficacy of ISIS 1048383 by subcutaneous injection,
administered by 3 different dosing regimens for 3 months, versus placebo. Approximately 160
TNF-alpha inhibitor-naïve rheumatoid arthritis patients will be evaluated at 32 sites in the
U.S. and Canada.